New progress in research on respiratory syncytial virus inhibitors
10.16438/j.0513-4870.2019-0732
- VernacularTitle:呼吸道合胞病毒抑制剂研究新进展
- Author:
Shu-jing XU
1
;
Xin-yong LIU
1
;
Peng ZHAN
1
Author Information
1. Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, Jinan 250012,China
- Publication Type:Research Article
- Keywords:
respiratory syncytial virus;
antiviral therapy;
rug target;
inhibitor
- From:
Acta Pharmaceutica Sinica
2020;55(4):597-610
- CountryChina
- Language:Chinese
-
Abstract:
Respiratory syncytial virus (RSV) is the main pathogen causing respiratory infections in infants, the elderly, and immunocompromised individuals. Currently, ribavirin and the humanized monoclonal antibody palivizumab are commonly used for lower respiratory tract infections caused by RSV. However, their clinical application has been limited by their efficacy, economy and safety. Therefore, it is necessary to develop new RSV inhibitors to meet the needs of clinical prevention and treatment. This paper selects typical research cases and reviews the research progress of different target inhibitors from the perspective of medicinal chemistry.
